Scrip is part of the Informa Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Diane OK means return to French market, as OC safety review continues

This article was originally published in Scrip

Executive Summary

Now that the European Commission has confirmed that Bayer's acne product, Diane (cyproterone acetate plus ethinylestradiol), should remain on the market but under strict prescribing conditions, attention will be turning to the fate of the combined hormonal contraceptives, which are also under scrutiny for their potential to cause thrombotic events.

Advertisement

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

SC022367

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel